## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.4% below STRENGTH zone (3.0-6.0%); PEG 1.46 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($339.73)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Corient Private Wealth LLC Increases Stake in Stryker Corporation $SYK**
- Source: MarketBeat | 20251215T095935 | Bullish | Relevance: 100%
- Corient Private Wealth LLC significantly increased its holdings in Stryker Corporation (NYSE:SYK) by 2.6% in the second quarter, bringing its total stake to 1,127,559 shares valued at approximately $446.1 million. This makes Stryker the 24th largest holding for Corient. Other major institutional investors, including Vanguard Group Inc. and State Street Corp, also increased their positions, while company insiders have sold a considerable number of shares recently.

**2. Stryker (NYSE:SYK) Has Announced That It Will Be Increasing Its Dividend To $0.88**
- Source: Simply Wall Street | 20251214T140801 | Bullish | Relevance: 100%
- Stryker Corporation (NYSE:SYK) has announced an increase in its periodic dividend to $0.88, effective January 30th, representing a 4.8% rise from the previous year. Although the dividend yield is relatively low at 0.9%, the payment is well-covered by earnings, with a projected payout ratio of 25% by next year. The company has a solid track record of consistent dividend growth and strong earnings per share, making it an attractive income stock.

**3. Stryker (SYK) Stock This Week: Dividend Hike, New COO, FDA Recall Watchlist â€” Outlook for the Week Ahead (Updated Dec. 12, 2025)**
- Source: ts2.tech | 20251213T050823 | Somewhat-Bullish | Relevance: 100%
- Stryker (SYK) experienced a volatile week, closing at $354.09, down 2.7%. Key developments included a dividend hike to $0.88 per share, the appointment of Spencer Stiles as President and COO, and an FDA Class I recall watch for a TMJ Bilateral Implant. Analysts remain broadly bullish despite Citigroup trimming its price target, while investors will monitor macro trends and company-specific updates next week.

**4. Taking Stock of Stryker (SYK) Valuation After Its Latest Dividend Increase and Confident Outlook**
- Source: Simply Wall Street | 20251212T093139 | Somewhat-Bullish | Relevance: 100%
- Stryker (SYK) recently increased its quarterly dividend by 5%, signaling confidence in its future cash generation and long-term earnings. Despite recent stock underperformance, its valuation narrative suggests it is 18.5% undervalued with a fair value near $433, driven by innovation and expected growth. However, an earnings-based view indicates a rich valuation with a P/E of 45.9 times, suggesting potential risk if growth or sentiment falters.

**5. Is the Market Bullish or Bearish on Stryker Corp?**
- Source: Sahm | 20251212T060831 | Somewhat-Bearish | Relevance: 100%
- Stryker Corp (NYSE: SYK) has seen a 12.62% increase in its short interest as a percent of float, with 4.21 million shares sold short, representing 1.16% of available shares. This rise in short interest signals a more bearish sentiment from investors, although the company's short interest is still lower than its peer group average of 5.60%.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $420 | $455 | -8% |
| 2025-11-14 | Truist Securiti | $400 | $392 | +2% |
| 2025-11-14 | Wells Fargo | $456 | $452 | +1% |
| 2025-11-14 | Needham | $448 | $448 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Buy |
| 2025-11-14 | Truist Securiti | main | Hold |
| 2025-11-14 | Wells Fargo | main | Overweight |
| 2025-11-14 | Needham | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($34.68M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $35M sold (6 transactions in 90 days).
2. Long-term trend broken: trading 5.9% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.46 suggests fair value with growth premium. Forward P/E 23.7x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($34.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.4B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.46 |
| Forward P/E | 23.7 |
| Current P/E | 26.1 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -4.7% to -0.4% (+4.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.4pp (needs >3.0% for momentum thesis). MRS_5 turning positive (1.8%) - potential reversal signal. Below SMA200 (0.94x), long-term trend not supportive. MACD histogram bearish (-1.46), momentum weakening. RSI neutral at 40. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.36% (CS: 24) | Neutral |
| RSI_14 | 40.5 | Neutral |
| MACD Histogram | -1.46 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 0.941x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $354.09
- **Stop Loss:** $339.73 (4.1% risk)
- **Target:** $368.45 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 69
- **Position Value:** $24,432.21
- **Portfolio %:** 24.43%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*